Pharmaron Beijing (300759) Q4 2025 earnings summary

Executive summary

• Achieved revenue of ¥14.10 billion in 2025, up 14.82% year-over-year, with strong growth in core business segments.

• Net profit attributable to shareholders was ¥1.66 billion, down 7.22% year-over-year due to a high base from prior-year investment gains.

• Adjusted net profit (excluding non-recurring items) rose 38.85% year-over-year to ¥1.54 billion.

• Operating cash flow increased 25.01% year-over-year to ¥3.22 billion.

• Over 3,300 global clients served, with new contract value up over 14% year-over-year.

Financial highlights

• Revenue: ¥14.10 billion (+14.82% YoY); Net profit: ¥1.66 billion (-7.22% YoY); Adjusted net profit: ¥1.54 billion (+38.85% YoY).

• Operating cash flow: ¥3.22 billion (+25.01% YoY); Free cash flow: ¥551.97 million.

• Basic EPS: ¥0.9443; Diluted EPS: ¥0.9393.

• Gross margin: 34.86%; R&D investment: ¥576 million, 4.09% of revenue.

• Total assets: ¥27.09 billion (+13.23% YoY); Net assets: ¥15.06 billion (+13.91% YoY).

Outlook and guidance

• 2026 revenue expected to grow 12–18% year-over-year based on new contracts and business trends.

• Strategic focus on integrated, international, multi-modality R&D service platform.

• Continued investment in AI, automation, and digitalization to enhance service efficiency and competitiveness.